Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial.
about
Prediction of changes in bone mineral density in postmenopausal women treated with once-weekly bisphosphonates.Vertebral anti-fracture efficacy of strontium ranelate according to pre-treatment bone turnoverThe assessment of fracture risk.Successes achieved and challenges ahead in translating biomarkers into clinical applications.Establishing reference intervals for bone turnover markers in healthy postmenopausal women in a nonfasting state.Should bisphosphonates be used for long-term treatment of glucocorticoid-induced osteoporosis?Recent advances in the use of serological bone formation markers to monitor callus development and fracture healingBone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions.Biochemical markers of bone turnover part II: clinical applications in the management of osteoporosisEfficacy of combined treatment with alendronate (ALN) and eldecalcitol, a new active vitamin D analog, compared to that of concomitant ALN, vitamin D plus calcium treatment in Japanese patients with primary osteoporosisBone resorption and fracture across the menopausal transition: the Study of Women's Health Across the Nation.Equilibrium-dependent bisphosphonate interaction with crystalline bone mineral explains anti-resorptive pharmacokinetics and prevalence of osteonecrosis of the jaw in rats.Prevalence of Osteoporosis and Its Associated Factors among Older Men with Type 2 Diabetes.Clinical application of biochemical markers of bone turnover.Does a history of non-vertebral fracture identify women without osteoporosis for treatment?Italian association of clinical endocrinologists (AME) position statement: drug therapy of osteoporosis.Biomarkers for osteoporosis management: utility in diagnosis, fracture risk prediction and therapy monitoring.Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of the Belgian Bone Club.Nitrates and bone turnover (NABT) - trial to select the best nitrate preparation: study protocol for a randomized controlled trial.Halofuginone prevents estrogen-deficient osteoporosis in mice.Reduced bone resorption by intake of dietary vitamin D and K from tailor-made Atlantic salmon: A randomized intervention trial.Current and future treatment options in osteoporosis.Biomarkers of bone turnover in diagnosis and therapy of osteoporosis: a consensus advice from an Austrian working group.Therapy for patients with CKD and low bone mineral density.Biochemical markers of bone turnover - uses and limitations.Bone markers and osteoporosis therapy.Hepatitis C virus coinfection as a risk factor for osteoporosis and fracture.The Utility of Biomarkers in Osteoporosis Management.Effect of antiresorptive drugs in the alveolar bone healing. A histometric and immunohistochemical study in ovariectomized rats.The use of biochemical markers of bone turnover in the clinical management of primary and secondary osteoporosis.The role of biochemical markers of bone turnover in osteoporosis management in clinical practice.Multidetector-row computed tomography is useful to evaluate the therapeutic effects of bisphosphonates in glucocorticoid-induced osteoporosis.Teriparatide in bisphosphonate-resistant osteoporosis: microarchitectural changes and clinical results after 6 and 18 months.Alendronate treatment in the revision setting, with and without controlled implant motion: an experimental study in dogs.Protective effect of Pycnogenol® on ovariectomy-induced bone loss in rats.[Biochemical markers of bone metabolism and their importance].Bisphosphonates
P2860
Q33569806-BEDEEB2D-2176-4ED0-8882-DEC2C36B8CBBQ33572186-83672E98-8EC5-4320-A986-56EFA355A529Q33685092-1380BC68-864A-4C96-9AB8-EADD523B8369Q33954585-95BBC853-C66A-4BE1-AC3E-3C1FEF360E27Q34171858-051848D9-5B3F-4F4C-8813-8966FAB05662Q34753158-17F7D76E-BB81-4757-A937-C7AFD2280A4DQ34759492-F91EE84E-E062-4A9F-B998-3809FC67EF26Q34960867-E89C952F-B5C7-48C3-A9F6-10F47672102EQ35053491-1BD5B0C8-977F-4907-883F-DA15FEACF3ADQ35092602-30C5B43A-B72A-4165-AAEB-220F9AE3E562Q36354523-4BC99780-F5EF-432D-8B8E-709635734B21Q36553571-C1A63CCF-CA90-462E-902A-30F90CD9D14CQ36582730-DFBFD60D-D2A8-4CF7-A087-7AAFB96A5D97Q36658915-E65941E5-46C4-4772-BFC9-A9AF818D95A2Q36840897-F2E0C7CA-A81B-4218-B182-E45E1FA11AA1Q37135281-E2DC6F29-5C57-4999-8CDF-D7C8C09DB845Q37176381-4B092299-1EB0-4721-B24D-E753D45E6A31Q37250572-533B65C3-B28F-4B33-BF20-64775D01298DQ37358034-2AE17FAA-EC1F-436A-97F1-CE3E98509FF3Q37642865-D3C4E741-7BA5-4918-9C88-4D34F4C92B9FQ37688337-99995879-AB5C-4076-9188-F33B984B2149Q37843715-B5435431-F9D5-4DA2-98F0-0D9D667A2D5EQ38034435-2D1464CB-42BF-4BAA-8AC5-B5AA461A90F1Q38150099-FB2DCA4E-C589-4E78-9E21-A05C31DED03BQ38176560-C298C214-D402-4F35-ADD1-94861865BE47Q38244170-4ECA0265-5408-42B7-A738-516B8BD49433Q38738823-1627E4D2-4B4C-4D31-9E69-737E120E9032Q38921875-631F045C-4B45-47E5-BBB7-E678E95D455DQ39557747-78619C73-8FCC-4F17-9820-E65D4F5D8273Q39975608-A155C433-F4F2-48B3-AFA9-8DB4950C097FQ43259341-550B1A28-BF73-4BD9-A223-0218B396075BQ44257423-200ECE43-6AC9-4382-ADF5-D70D0D481183Q46040516-3AEC9A0D-F0EC-40ED-BE05-84E55BC9107AQ46781503-A64A2F93-1743-4381-99F7-F5A7C8679923Q51445255-99763AD0-8D15-46AB-84D1-DE3E7AF24FB1Q54325714-06F0089B-C3F6-45EB-963F-EEC426BE4B79Q58971260-7C77CF0F-FA53-451F-961F-4779A9BCA549
P2860
Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Pretreatment levels of bone tu ...... e fracture intervention trial.
@en
type
label
Pretreatment levels of bone tu ...... e fracture intervention trial.
@en
prefLabel
Pretreatment levels of bone tu ...... e fracture intervention trial.
@en
P2093
P356
P1476
Pretreatment levels of bone tu ...... e fracture intervention trial.
@en
P2093
Art Santora
Dennis M Black
Douglas C Bauer
Fracture Intervention Research Group
Marc C Hochberg
Patrick Garnero
Pierre Delmas
Susan K Ewing
P304
P356
10.1359/JBMR.051018
P577
2005-10-31T00:00:00Z